A B S T R A C T Although the stomach is mainly known for its ability to secrete hydrochloric acid, there is increasing evidence that the gastric mucosa also secretes bicarbonate. A simple method for simultaneous measurement of gastric HCO-secretion and H+ secretion was developed from a two-component model of gastric secretion. The method, which is based upon gastric juice volume, H+ concentration, and osmolality, was validated both in vitro and in vivo. In 14 healthy human beings, basal gastric HCO-secretion averaged 2.6 mmol/h (range, 0.7-8.7 mmol/h). Basal HCO3 secretion was "50% of basal H+ secretion and there was a significant correlation between basal HCO-and H+ secretion in individual subjects (r = 0.79). HCO damage by luminal acid and pepsin (1), there is limited information on the amount of bicarbonate secreted by the stomach (2). Attempts to quantitate gastric HCO-secretion have been hampered by concomitant H+ secretion, which converts HCO-to CO2. One approach to this problem has been to use agents that reduce H+ secretion, such as cimetidine (3). For quantitative purposes, it is assumed that the antisecretory agent blocks H+ secretion completely and that the antisecretory agent has no effect per se on HCO3 secretion. However, it is uncertain whether either of these assumptions is valid (2). A second method to avoid concomitant H+ secretion has been to measure the secretion from antral mucosa in vitro (4) or an antral pouch in vivo (5). These methods assume that no acidsecreting parietal cells are present in the antral preparation, an assumption which sometimes may not be true (5). Moreover, these techniques are not readily applicable to humans. A third approach has been to study gastric HCO-secretion in patients with achlorhydria (6). It is uncertain, however, whether alkaline secretion rates in these patients with atrophic fundic gastritis are representative of HCO-secretion rates in healthy individuals whose stomachs secrete HW.
INTRODUCTION
Although bicarbonate secretion probably plays an important role in protecting the gastric epithelium from Received for publication 21 December 1982 and in revised form 16 March 1983. damage by luminal acid and pepsin (1) , there is limited information on the amount of bicarbonate secreted by the stomach (2) . Attempts to quantitate gastric HCO-secretion have been hampered by concomitant H+ secretion, which converts HCO-to CO2. One approach to this problem has been to use agents that reduce H+ secretion, such as cimetidine (3) . For quantitative purposes, it is assumed that the antisecretory agent blocks H+ secretion completely and that the antisecretory agent has no effect per se on HCO3 secretion. However, it is uncertain whether either of these assumptions is valid (2) . A second method to avoid concomitant H+ secretion has been to measure the secretion from antral mucosa in vitro (4) or an antral pouch in vivo (5) . These methods assume that no acidsecreting parietal cells are present in the antral preparation, an assumption which sometimes may not be true (5) . Moreover, these techniques are not readily applicable to humans. A third approach has been to study gastric HCO-secretion in patients with achlorhydria (6) . It is uncertain, however, whether alkaline secretion rates in these patients with atrophic fundic gastritis are representative of HCO-secretion rates in healthy individuals whose stomachs secrete HW.
A fourth method for estimating gastric HCO,3 secretion is to measure the volume, H+ concentration, and chloride concentration of gastric juice and use a mathematical, two-component model of gastric secretion (7) (8) (9) (10) . However, the equations derived from a two-component model of gastric secretion have never been validated as a method for measuring gastric HCO-secretion. The present studies had two major purposes. First, equations were derived from a two-component model of gastric secretion 
It is apparent that AG Vcj[H'1 (4) and that (9, 10, 13, 14) . From references 10 
RESULTS
In vitro validation. A pure "parietal" solution containing 160 mmol/liter HC1 was prepared from a stock solution and the concentration of HC1 confirmed by titration to pH 7.00 with 0.1 N NaOH. In addition to the "parietal" solution, 16 "nonparietal" HCO3-containing solutions were prepared. These solutions contained from 6 .0 to 88.1 mmol/liter of bicarbonate.
Sufficient NaCl was added to the 16 Vp (r = 1.00); and [BNPI (r = 0.96). The lowest osmolality of a mixed sample, 238 mosM/kg, occurred when 30.0 ml "parietal" solution was added to 20 .0 ml of a "nonparietal" solution containing 88.1 mmol/ liter of bicarbonate.
In vivo validation. The purpose of these in vivo studies was to determine whether an intragastric infusion of an HCO--containing "nonparietal" solution, which simulates an increase in HCO secretion by the stomach, could be detected quantitatively by our method. To do this, an intragastric HCO3 infusion was superimposed on steady-state gastric secretion induced by a continuous intravenous infusion of 0.1-0.2 1sg/ kg/h pentagastrin (Peptavlon, Ayerst Laboratories, New York) in eight subjects. These pentagastrin doses were submaximal in seven of the eight subjects (mean acid outputs were 60±7% of the maximal acid response to 6.0 ag/kg s.c. pentagastrin). In one subject, the dose of pentagastrin (0.2 jg/kg/h) proved to be maximal. Thus, for the eight subjects, acid secretion during pentagastrin infusion ranged from 27 to 100% of maximal.
After basal gastric juice and saliva were collected for two 15-min periods, the intravenous infusion of pentagastrin was begun (volumetric infusion pump model 922; IMED Corp., San Diego, CA). Pentagastrin was infused for twelve 15-min periods. During the seventh 15-min period of intravenous pentagastrin infusion, one of eight HCO3-containing test solutions was infused into the stomach (IMED infusion pump) through a small polyethylene catheter attached to the nasogastric tube. The HCO--containing solutions were approximately isotonic (osmolality, 293±2 mosM/kg; plasma osmolality, 294±2 mosM/kg). The HCO3 concentration of the solutions varied from 0 to 90.0 mmol/ liter; the other electrolytes were Na+ and Cl-. The volume of the solution infused into the stomach varied from 12.0 to 56.0 ml. One of us selected the solution and volume to be infused; the other carried out measurements of VGJ, [HGJ] , and OSMGJ without knowledge Of VNP or [BNPI-Infusion of the test solution into the stomach was started 2 min after the beginning of the seventh 15-min period of pentagastrin infusion and was stopped 3 min before the end of the period (i.e., the infusion lasted 10 min). The test solution also contained 2 g/dl polyethylene glycol (PEG) as a nonabsorbable marker in order to estimate completeness of recovery of gastric juice (16) .
An example of an experiment using this protocol is shown in Fig. 1 with the amounts of fluid and HCO-actually infused into the stomach during period 7.
Results from experiments in which eight healthy subjects were studied according to this protocol are shown in Fig. 2 . There was a good correlation between calculated and actual values for (a) the increase in calculated HCO-secretion during period 7; (b) the increase in VNP during period 7; and (c) HCO3
concentration of the simulated secreted fluid during period 7. PEG recovery during period 7 averaged 93±3%.
Basal gastric secretion. Basal HCO-secretion in 14 subjects averaged 2.6±0.6 mmol/h, which was -50% of basal H+ secretion (4.9±0.9 mmol/h). There was a significant correlation between basal HCO-and H+ secretion in individual subjects (r = 0.79, P < 0.001).
Basal [HGj] 15- min periods. Gastric juice and saliva were collected as described previously. Salivary output was unaffected by the prostaglandin compound. As shown in Fig. 5 (upper left), there was a doserelated increase in HCO-secretion in response to the PGE2 analogue, with the peak response following 0.75 mg. With this dose, HCO-secretion increased from 4.3 to 6.1 mmol/2 h (P < 0.05), and [BNP] increased from 45.0 to 74.9 mmol/liter (P < 0.005, Fig. 5 , lower right). PGE2 did not stimulate nonparietal volume secretion; in fact, VNP decreased significantly (Fig. 5,  upper right) . PGE2 also decreased parietal volume secretion significantly. The 0.75-mg dose of PGE2, for example, reduced pentagastrin-stimulated parietal secretion by 73.4 ml/2 h (P < 0.05, Fig. 5, lower left) . Thus, this dose of prostaglandin reduced H+ secretion more than it increased HCO-secretion (11.7 mmol/2 h vs. 1.8 mmol/2 h).
DISCUSSION
Validity of basic assumptions. One assumption of the two-component model of gastric secretion is that H+ is secreted at a concentration of 160 mmol/liter, even at submaximal rates of acid secretion (7, 10, 12, 13 Fig. 2 . Thus, our in vivo validation studies indirectly support the assumptions that
[Hp] = 160 mmol/liter and OSMp = 1.06 OSMPL when acid output ranges from 27 to 100% of maximal. Our own experimental data from highly acid specimens of gastric juice also support these assumptions (Fig. 4) . That the nonparietal component of gastric secretion is approximately isotonic to plasma is supported by several previous studies in animals and humans (9, 10, 13, 14) and by results in our patient with pentagastrinfast achlorhydria and isotonic gastric juice (Fig. 4) However, the healthy stomach is highly impermeable to passive diffusion of ions from the lumen into the mucosa (17) . It has even been suggested that the disappearance of H+ from the lumen by apparent dif- fusion into the mucosa may actually represent surface neutralization by bicarbonate secretion (10) . Nevertheless, the rate of apparent absorption of H+ by the stomach is <0.1%/min (18, 19) , so that under the conditions of our experiments, in which secreted gastric juice was aspirated from the stomach continuously rather than remaining in contact with the gastric mucosa for a prolonged period, it is likely that absorption of H+ and other ions by gastric mucosa was negligible. Thus, our validation experiments indicate that it is possible to estimate gastric HCO-secretion (BS) from measurements of gastric juice volume, H+ concentration, and osmolality. In Fig. 6, a nomogram had been assumed by Hollander (7) and by Makhlouf et al. (9, 10) , because it could be stimulated significantly by pentagastrin and bethanechol. Furthermore, pentagastrin-stimulated nonparietal volume secretion could be decreased significantly by the prostaglandin E2 analogue. Thus, our data support Hunt's suggestion that both parietal and nonparietal volume secretion (and their ratios) can vary under different experimental conditions (8, 20) .
Despite our agreement with previous studies regarding basal nonparietal volume secretion, our calculated values for basal HCOi secretion are greater than those that have been estimated previously (3, 10, 21) . Thus, we estimated that the healthy human stomach secreted -2.6 mmol HCO /h. Previous two-component models, which automatically assumed that nonparietal secretion had a [BNP] equal to plasma (9, 10) (25) . More recently, Turnberg and his associates (26) (27) (28) used microelectrodes and recorded the pH near the gastric mucosal surface to be as high as 8.65, 7.95, and 8.10 in rabbits, rats, and humans, respectively, when luminal pH was -2.0. As an example, a pH of 8.10 corresponds to a HCO3 concentration of 83 mmol/liter when Pco2 = 40 mmHg. Furthermore, in our experience with 13 patients with pentagastrinfast achlorhydria, maximal gastric juice pH ranged from 7.86 to 8.48 (Cowley, Y., and M. Feldman. Unpublished data.). Thus, current evidence suggests that both the HCO3 concentration and the pH of nonparietal gastric secretion are much higher than plasma.
Because the gastric lumen is negatively charged (-40 mV) with respect to the mucosa (17, 19 ), HCO3 appears to be secreted by the mucosa into gastric juice against both an electrical and a chemical gradient. This suggests that HCO-secretion in humans is, at least in part, an active process. A similar conclusion has been reached in previous animal studies that measured HCOi secretion in vitro by titration with HC1 (and which, therefore, did not assess HC037 concentration of secreted fluid) (2, 29) . Because stimulation of HCO-secretion is not accompanied by a change in potential difference, it has been suggested that active HCOi secretion is an electroneutral process, which is possibly mediated by luminal Cl-/HCO& exchange (2) . In support of this concept, fundic bicarbonate secretion can be blocked in vitro by removing chloride from luminal fluid (2 (2) . Bethanechol caused a simultaneous and significant increase in pentagastrin-stimulated H+ and HCOs secretion (9.0 and 4.1 mmol/2 h, respectively). Although net acid output increased somewhat during bethanechol infusion, this was not a significant change (Table  I) . Thus, the significant increase in H+ secretion during bethanechol infu-sion was masked somewhat by a concurrent stimulation of HCO? secretion. The prostaglandin E2 analogue also caused an increase in gastric HCO-secretion while causing a much larger decrease in gastric H+ secretion. Therefore, the significant reduction in net acid output in gastric juice due to the prostaglandin E2 analogue was more due to inhibition of H+ secretion than to stimulation of HCO-secretion. It is possible that other prostaglandin compounds will affect the relationship between gastric HCO3-and H+ secretion differently (30) .
